The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.
aryl hydrocarbon receptor
breast cancer
endocrine therapy
intratumoral aromatase
polymorphisms
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
01
2021
accepted:
22
04
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
The aryl hydrocarbon receptor (AhR) is a master regulator of multiple pathways involved in breast cancer, and influences the estrogen receptor alpha (ER) and aromatase/CYP19A1. The purpose of this study was to elucidate the interplay between intratumoral levels of AhR and aromatase, patient characteristics (including
Identifiants
pubmed: 34094928
doi: 10.3389/fonc.2021.642768
pmc: PMC8174786
doi:
Types de publication
Journal Article
Langues
eng
Pagination
642768Informations de copyright
Copyright © 2021 Tryggvadottir, Sandén, Björner, Bressan, Ygland Rödström, Khazaei, Edwards, Nodin, Jirström, Isaksson, Borgquist and Jernström.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Clin Pharmacol. 2017 Mar;83(3):562-571
pubmed: 27747906
Mol Genet Metab. 2011 Sep-Oct;104(1-2):180-4
pubmed: 21742528
Virchows Arch. 2020 Aug;477(2):317-320
pubmed: 32080761
Med Res Rev. 2020 May;40(3):972-1001
pubmed: 31721255
Nat Commun. 2019 Mar 8;10(1):1125
pubmed: 30850589
Mol Cell Biochem. 2017 Jan;425(1-2):59-75
pubmed: 27796684
Cancer Chemother Pharmacol. 2011 Nov;68(5):1263-71
pubmed: 21442439
Chem Res Toxicol. 2003 Jul;16(7):807-16
pubmed: 12870882
J Steroid Biochem Mol Biol. 2005 May;95(1-5):35-9
pubmed: 16024247
Environ Health Perspect. 2016 May;124(5):601-10
pubmed: 26372666
Toxicol Sci. 2007 Apr;96(2):255-67
pubmed: 17234648
Cell Death Dis. 2014 Jan 30;5:e1038
pubmed: 24481452
Front Oncol. 2020 Feb 06;10:80
pubmed: 32117735
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7931-7
pubmed: 25550834
Breast Cancer Res Treat. 2015 Jun;151(2):373-84
pubmed: 25935582
Int J Mol Sci. 2020 Sep 11;21(18):
pubmed: 32932962
Int J Mol Sci. 2019 Feb 26;20(5):
pubmed: 30813617
J Cancer Ther. 2013 Sep;4(7):1177-1186
pubmed: 25068070
Arch Toxicol. 2017 Jul;91(7):2497-2513
pubmed: 28508231
Br J Cancer. 2016 Jul 26;115(3):382-90
pubmed: 27280635
Mol Endocrinol. 2010 Jan;24(1):33-46
pubmed: 19901195
Cell. 2011 Oct 28;147(3):489-91
pubmed: 22036556
Control Clin Trials. 1990 Apr;11(2):116-28
pubmed: 2161310
Horm Cancer. 2014 Feb;5(1):11-21
pubmed: 24078229
BMC Cancer. 2016 Mar 31;16:256
pubmed: 27029552
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
Cancer Causes Control. 2012 Aug;23(8):1307-16
pubmed: 22695757
Mol Cell Endocrinol. 1999 Nov 25;157(1-2):105-19
pubmed: 10619402
Nature. 2003 May 29;423(6939):545-50
pubmed: 12774124
Mol Cell Biol. 2003 Mar;23(6):1843-55
pubmed: 12612060
Breast Cancer Res. 2019 Mar 12;21(1):40
pubmed: 30867002
Mol Cell Endocrinol. 2010 Apr 12;317(1-2):8-13
pubmed: 19962423
Breast Cancer Res Treat. 2017 Feb;161(3):399-407
pubmed: 27900579
Dtsch Arztebl Int. 2010 Jan;107(4):50-6
pubmed: 20165700
Arch Toxicol. 2018 Apr;92(4):1639-1655
pubmed: 29362861
PLoS One. 2018 Jan 10;13(1):e0190619
pubmed: 29320557
Int J Mol Sci. 2013 Sep 13;14(9):18973-88
pubmed: 24065098
BMC Cancer. 2009 Jun 16;9:185
pubmed: 19531212
J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):237-41
pubmed: 19883757
Int J Mol Sci. 2020 Jul 24;21(15):
pubmed: 32722276
Crit Rev Eukaryot Gene Expr. 2008;18(3):207-50
pubmed: 18540824
Clin Cancer Res. 2008 Feb 1;14(3):811-6
pubmed: 18245543
Nat Rev Cancer. 2014 Dec;14(12):801-14
pubmed: 25568920
PLoS Med. 2012;9(5):e1001216
pubmed: 22675273
Nat Rev Immunol. 2019 Mar;19(3):184-197
pubmed: 30718831
Curr Opin Toxicol. 2017 Feb;2:24-29
pubmed: 28459113
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):239-44
pubmed: 14623517
J Hematol Oncol. 2019 Dec 21;12(1):140
pubmed: 31864424